← Human Trials & Peer-Reviewed Studies
Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial
Plain-language guide to PMID 23972263 (2013): single-blind randomized controlled trial study of Octreotide and Somatostatin.
Key Facts
- PMID
- 23972263
- Journal
- Lancet (London, England)
- Year
- 2013
- Study type
- Randomized Controlled Trial
- Authors
- Caroli A et al. (21 authors)
- DOI
- 10.1016/S0140-6736(13)61407-5
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Octreotide and Somatostatin.
The researchers aimed to assess the effect of 3 years of octreotide-LAR treatment on kidney and cyst growth and renal function decline in participants with this disorder.
Who Took Part
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
Study physicians and nurses were aware of the allocated group; participants and outcome assessors were masked to allocation.
How the Study Was Run
The researchers set it up as a randomized, single-blind, placebo-controlled, multicenter, parallel-group and pilot study.
Because people in this Octreotide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Only one side, usually the participants, was kept unaware of whether Octreotide was given.
A placebo (an inactive look-alike) gave the Octreotide group a baseline to be compared against.
More than one site took part, so the participants came from several places.
The researchers did an academic, multicentre, randomised, single-blind, placebo-controlled, parallel-group trial in five hospitals in Italy.
The primary endpoint was change in total kidney volume (TKV), measured by MRI, at 1 year and 3 year follow-up.
Analyses were by modified intention to treat.
This study is registered with ClinicalTrials.gov, NCT00309283.
What Was Measured
PubMed files the paper under topics including Cholecystitis, Acute, Cholelithiasis, Disease Progression, Gastrointestinal Agents, Italy, Kidney and Kidney Failure, Chronic.
What This Means in Plain Language
The paper is a randomized, single-blind and placebo-controlled study of Octreotide and Somatostatin.
Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2013 (Lancet (London, England)), a journal based in England.
More context: the Octreotide compound page and the Somatostatin compound page, all human trials.
Our Notes on the Compounds
Octreotide: An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.